Zhang J, Gong W-H, Li Y, Zhang H-Y, Zhang C-X
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7568. doi: 10.26355/eurrev_202007_22232.
Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, "Hsa-miR-337 inhibits non-small cell lung cancer cell invasion and migration by targeting TCF7, by J. Zhang, W.-H. Gong, Y. Li, H.-Y. Zhang, C.-X. Zhang, published in Eur Rev Med Pharmacol Sci 2019; 23 (15): 6548-6553-DOI: 10.26355/eurrev_201908_18540-PMID: 31378895" has been withdrawn. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18540.
由于本文涉嫌研究不当行为，且通讯作者未回应我们关于证明数据和图表原创性的要求，J. Zhang、W.-H. Gong、Y. Li、H.-Y. Zhang、C.-X. Zhang发表于《欧洲医学与药理学评论》2019年；23(15):6548 - 6553 - DOI: 10.26355/eurrev_201908_18540 - PMID: 31378895的《Hsa - miR - 337通过靶向TCF7抑制非小细胞肺癌细胞的侵袭和迁移》已被撤回。出版方对由此可能造成的不便表示歉意。https://www.europeanreview.org/article/18540
